HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases.

The laboratory of Prof. Lars Zender identified Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) as a key regulator of liver regeneration. Suppression of MKK4 gene expression by small RNA molecules unlocks the regenerative capacity of hepatocytes even in severely diseased livers. These findings paved the way for the unique and promising therapeutic concept to develop small molecule MKK4 inhibitors to treat acute and chronic liver diseases. In particular, following thorough characterization of the underlying molecular mechanism of action of drug candidates, there is potential for the development in non-alcoholic steatohepatitis (NASH).

Press releases

Tubingen (Germany), October 17, 2019

HepaRegeniX GmbH announces management changes: Dr. Michael Lutz appointed as new CEO/Managing Director.

View PDF | 50kb

Tubingen (Germany), January 05, 2017

HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases.

View PDF | 310kb


Tübingen, 17. Oktober 2019

HepaRegeniX GmbH kündigt Management-Wechsel an: Dr. Michael Lutz wird zum neuen Geschäftsführer ernannt. (Pressemittung in englischer Sprache)

PDF anzeigen | 50kb

Tübingen, 5. Januar 2017

HepaRegeniX GmbH erhält €9 Mio. in Serie-A-Finanzierungsrunde für die Entwicklung von Kinaseinhibitoren zur Behandlung akuter und chronischer Lebererkrankungen.

PDF anzeigen | 335kb

© 2016-2019 HepaRegeniX GmbH. All rights reserved.